An experimental therapy that families of children with Angelman syndrome had followed for years failed its final-stage trial, missing both the primary endpoint and the key secondary endpoint. There is still no approved treatment that addresses the underlying cause of the condition.
Ultragenyx reported that its Phase 3 Aspire study of apazunersen, previously known as GTX-102, did not achieve improvement in Bayley-4 cognitive raw scores from baseline, nor in a composite measure called the Multidomain Responder Index. The company said the randomized groups were comparable at baseline and that no differences emerged between the treated and control groups that could support efficacy.
Ultragenyx estimates that Angelman syndrome affects about 60,000 people across the geographies where it markets its products. For those families, this is the second kind of news that rare disease communities live with. The first is a promising early result. The second is what happens when a large, well-designed trial does not confirm it.
Both the Primary and Key Secondary Goals Went Unmet
The Aspire study enrolled approximately 129 participants aged four to 17 with a genetically confirmed diagnosis of full maternal UBE3A gene deletion, according to the company's enrollment announcement. Participants were randomized evenly to receive the drug by intrathecal injection through lumbar puncture or to a sham comparator group for 48 weeks, with the sham group eligible to cross over to treatment afterward. The design is registered on ClinicalTrials.gov.
Apazunersen is an antisense oligonucleotide delivered into the fluid surrounding the spinal cord. It was designed to inhibit a molecule that silences the paternal copy of the UBE3A gene, so that the paternal copy could compensate for the missing or damaged maternal copy.
In the trial, no differences appeared between treated and control groups on Bayley cognition raw scores or on the responder index, whether measured as net response or as mean changes across the five individual endpoints that make up the composite. Those five domains are cognition, receptive communication, behavior, gross motor function, and sleep. The safety profile was consistent with earlier Phase 1/2 testing, so the failure was one of effect rather than of tolerability.
Chief executive Emil Kakkis said the company was disappointed by the result given what it had observed in earlier testing, and "we are disappointed for the global patient community who has invested so much" in early-stage research, in the company's statement.
Families Who Enrolled Face an Uncertain Next Step
Angelman syndrome causes cognitive impairment, motor impairment, balance issues, and debilitating seizures. Most people with the condition do not speak, some cannot walk, and anxiety and disturbed sleep can be serious challenges. Lifespan is normal, but people with the condition require continuous care and are unable to live independently, which means families plan for decades.
That combination is what makes a trial failure land differently here than in a condition with shorter horizons. The families involved were not seeking a modest improvement in a laboratory value. They were participating in an attempt to change what their child's adult life would look like.
Practically, the company has said it will evaluate the apazunersen program in light of the outcome and make a decision on its disposition, language that leaves open the possibility of changes or discontinuation. Families with children currently receiving the drug through the trial or an extension study should direct questions about continued access to their study site investigator, who is the person with current information about that specific protocol.
Ultragenyx also said it will assess its planned operations and implement significant expense reductions while supporting its commercial business. Corporate restructuring after a failed lead program is common, and it can affect timelines for other rare disease programs a company is running. The company maintains a public pipeline listing covering its other candidates.
Early Promise, Late Disappointment, and the Gap Between Them
Apazunersen carried more regulatory encouragement than most experimental drugs. It received Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the Food and Drug Administration, plus Orphan and PRIME designations from the European Medicines Agency.
None of those designations is a statement that a drug works. They are mechanisms to speed development and review for conditions with serious unmet need, granted on the strength of early data and the absence of alternatives. A drug can hold all of them and still fail.
The gap between the Phase 1/2 results and the Phase 3 outcome is the part worth understanding, because it recurs across rare disease research. Early-stage studies are usually small, often lack a control group, and rely on outcome measures that can move for reasons unrelated to the drug, including natural development in growing children, family expectation, and the additional therapy and attention that trial participation brings.
A randomized controlled trial with a sham comparator is designed to strip those influences out. When it does, effects that looked real sometimes disappear. That is the mechanism working correctly, even when the result is painful.
The Program's Future Now Sits with the Company
What happens next is not yet defined. Ultragenyx has not announced whether it will discontinue apazunersen, analyze subgroups, or pursue a different dosing approach, and it has not published a timeline for that decision. Its Angelman program page remains live.
A single failure does not close the biological rationale, which rests on solid genetics. It does mean the nearest option is further away than it appeared a week ago.
Current care for Angelman syndrome remains supportive and symptom-directed, including seizure management, physical and occupational therapy, communication support, and sleep interventions. None of that changes because of this result, and families should not alter any existing treatment without speaking with their child's clinicians.
Full trial data have not been published or presented. When they are, they will be the basis for any judgment about whether a subset of patients responded or whether the outcome measures captured what mattered to families.
Key Questions Answered
What is Angelman syndrome? A rare neurogenetic disorder caused by loss of function of the maternally inherited UBE3A gene, producing cognitive impairment, motor and balance problems, and seizures. It generally occurs spontaneously rather than being inherited.
What did the trial test? Apazunersen, an antisense therapy delivered into the spinal fluid, was designed to prevent silencing of the paternal copy of the UBE3A gene so it can compensate for the missing maternal copy.
What were the results? The study missed its primary endpoint of change in Bayley-4 cognitive raw score and its key secondary endpoint on the Multidomain Responder Index. No efficacy differences were observed.
Was the drug unsafe? No. The safety profile was consistent with earlier Phase 1/2 testing. The trial failed on effectiveness, not on tolerability.
Are there other approved treatments? No therapy is approved for Angelman syndrome. Care remains supportive, including seizure management, therapy services, communication support, and sleep interventions.
Why did earlier results look better? Early-stage studies are small, often uncontrolled, and can be influenced by natural development, expectation, and the extra support trial participation brings. Randomized trials are designed to remove those effects.
What happens to families in the trial? The company says it will evaluate the program and decide its disposition. Questions about continued access should go to the study site investigator.
